New weapon against deadly malaria tested in global trial
NCT ID NCT04675931
Summary
This study tested a new intravenous drug called cipargamin for treating severe malaria, a life-threatening disease. It involved 254 adults and children with severe malaria and aimed to find a safe and effective dose. The goal was to develop a new treatment option, especially as resistance to current standard drugs is spreading.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEVERE MALARIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Burkina Faso, 2208, Burkina Faso
-
Novartis Investigative Site
Ouagadougou, Burkina Faso
-
Novartis Investigative Site
Abidjan, 13BP972, Côte d’Ivoire
-
Novartis Investigative Site
Agboville, BP 154, Côte d’Ivoire
-
Novartis Investigative Site
Kinsasha, Democratic Republic of Congo, BP 7948, Democratic Republic of the Congo
-
Novartis Investigative Site
Siaya, 2300, Kenya
-
Novartis Investigative Site
Manhiça, Maputo Province, 1929, Mozambique
-
Novartis Investigative Site
Kigali, BP 4560, Rwanda
-
Novartis Investigative Site
Tororo, 10102, Uganda
Conditions
Explore the condition pages connected to this study.